Project Grant R01NS140967
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$635K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Boston, MA 02118, USA
Similar Awards
The National Cancer Institute awarded a $225,101 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Baylor College of Medicine to conduct research aimed at understanding how the MYCN oncogene drives an immune-suppressive tumor microenvironment in neuroblastoma. The research will (1) determine how MYCN rewires T cell metabolism to promote immune suppression, and (2) elucidate how MYCN-induced lipogenesis contributes to a suppressive tumor immune microenvironment. This research is vital...
The National Cancer Institute (NCI) awarded a $431,968 Project Grant under the Cancer Biology Research (CFDA 93.396) program to Baylor College of Medicine. The grant, awarded on August 15, 2024, will fund a 5-year research project to elucidate how the oncogenic MYCN gene drives metabolic changes in neuroblastoma tumors that suppress the immune system, as well as explore methods to modulate the tumor microenvironment to enhance immunotherapies for high-risk, MYCN-amplified neuroblastoma. The...
This $644,967 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research at the University of Pittsburgh focused on understanding the role of the SMARCD3/BAF60C protein in the development and metastasis of medulloblastoma, an aggressive brain cancer. The research aims to delineate how SMARCD3 expression is regulated by the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $576,659 to Emory University to investigate tumor and host immune signatures associated with disparities in outcomes following GD2 immunotherapy in neuroblastoma patients. The key objectives are to: Perform tumor-based single cell genomic, proteomic, and functional investigations before and after chemoimmunotherapy to determine tumor immune microenvironment markers influencing...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research on encapsulated cell-based oncolytic virus therapy for brain tumors, specifically glioblastoma (GBM). The $420,251 award, granted on May 6, 2025, with a completion date of March 31, 2030, aims to enhance the therapeutic efficacy of mesenchymal stem cell...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will support research to dissect the cellular composition and immune response within the glioblastoma (GBM) tumor microenvironment. The $687,279 award to Beth Israel Deaconess Medical Center, Inc. (Bidmc) will leverage archival patient samples and mouse models to uncover the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding research to advance mRNA-based gene therapies for the treatment of pediatric high-grade gliomas, specifically diffuse midline glioma (DMG). The $142,452 award, effective September 18, 2024 through August 31, 2026, supports the development and evaluation of non-toxic lipid...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $460,940 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The University of Texas MD Anderson Cancer Center. This 2-year grant, effective June 1, 2025, will support research to investigate how glioma-associated germline risk alleles impact neurodevelopmental trajectories. Specifically, the research will leverage single-cell and bulk profiling...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program provides $656,513 in funding to Children's Hospital Medical Center in Cincinnati, Ohio to identify germline (inherited) modifiers of neurofibromatosis type 1 (NF1) tumors. The research aims to expand the study population with NF1-related plexiform neurofibromas and/or optic...
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...